http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CZ-300438-B6
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b9baa73ae162b7cac903c48067885e73 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1676 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2095 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate | 2003-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0aacccb4cec3467d487fcd1030bcaf40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93c5b024cedb9415e4ce97cd8c128121 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd85658fd4aeef1af156e3121fe288c1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f3966ad5d202f786571ce294604f46d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb0272c81c479ace3d958ef42c818342 |
| publicationDate | 2009-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CZ-300438-B6 |
| titleOfInvention | Method for immediate release oral solid dosage form of active substance containing polymorphic form of finasteride as active substance |
| abstract | A process for the preparation of an immediate-release oral solid dosage form comprising as active ingredient a polymorphic form of finasteride, the essence of which consists in that an aqueous suspension containing 5 to 50% by weight of polymorphic form of finasteride, based on the total weight of the suspension, and 0.1 to 50% by weight of at least one anionic surfactant, based on the weight of the polymorphic form of finasteride, is ground to achieve a particle size distribution of the polymorphic form of finasteride such that at least 10% of the particles have a size of at most 2 .mu.m, at least 50% of the particles have a size of at most equal to 7 .mu.m and at least 90% of the particles have a size of at most 17 .mu.m, after which the aqueous suspension obtained is injected in a fluidized bed onto a solid particulate hydrophilic carrier having a particle size distribution such that at least 90% of the particles have a size greater than 40. .mi.m, not more than 10% of the particles have a size greater than 200 .mi.m and at least 99% of the particles have a size of at most 300 .mi.m. |
| priorityDate | 2003-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 63.